About Dynein axonemal heavy chain 8
Dynein axonemal heavy chain 8 (DNAH8) is a protein
from Homo sapiens identified by UniProt accession
Q96JB1, 4490 residues long.
MolForge cross-references it against 0 known binders and
654 disease associations.
Target properties
| Protein name | Dynein axonemal heavy chain 8 |
|---|
| UniProt accession | Q96JB1 |
|---|
| Gene | DNAH8 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4490 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (654)
Diseases linked to this target (Open Targets).
- spermatogenic failure 46 · score 0.71
- primary ciliary dyskinesia · score 0.57
- bone density · score 0.42
- urate measurement · score 0.42
- smoking status measurement · score 0.26
- PHF-tau measurement · score 0.16
- drug use measurement · score 0.14
- genetic disorder · score 0.12
- Recurrent respiratory infections · score 0.12
- Recurrent infections · score 0.12
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4490 residues)
MMKLYIDNAA PDKLKGLCIF FVRCRNDVAI NVKTIQEEAL FTVLDASKGL LNGIRDMLAN IFLPAVLATN NWGALNQSKQ GESEKHIFTE TINRYLSFLD GARISIEGTV KLKTIDNVNF SKLHTFEEVT AAASNSETVH QLEEVLMVWY KQIEQVLIES EQMRKEAGDS GPLTELEHWK RMSAKFNYII EQIKGPSCKA VINVLNVAHS KLLKNWRDLD ARITDTANES KDNVRYLYTL EKVCQPLYNH DLVSMAHGIQ NLINAIRMIH GVSRYYNTSE RMTSLFIKVT NQMVTACKAY ITDGGLNHVW DQETPVVLKK IQDCIFLFKE YQASFHKTRK LISESSGEKS FEVSEMYIFG KFEAFCKRLE KITEMITVVQ TYSTLSNSTI EGIDIMAIKF RNIYQGVKKK QYDILDPRRT EFDTDFLDFM TKINGLEVQI QAFMNSSFGK ILSSQQALQL LQRFQKLNIP CLGLEINHTI ERILQYYVAE LDATKKLYHS QKDDPPLARN MPPIAGKILW VRQLYRRISE PINYFFKNSD ILSSPDGKAV IRQYNKISYV LVEFEVVYHT AWIREISQLH YALQATLFVR HPETGKLLVN FDPKILEVVR ETKCMIKMKL DVPEQAKRLL KLESKLKADK LYLQGLLQYY DELCQEVPSV FVNLMTPKMK KVESVLRQGL TVLTWSSLTL ESFFQEVELV LDMFNQLLKK ISDLCEMHID TVLKEIAKTV LISLPESGAT KVEDMLTLNE TYTKEWADIL NHKSKHVEEA VRELISIFEQ IYEVKYTGKV GKQSEQRKHV VFGSETGEGE NNDYEANIVN EFDTHDKEDE FKKECKEVFA FFSHQLLDSL QKATRLSLDT MKRRIFVASL YGRKQSEDII SFIKSEVHLA IPNVVMIPSL DDIQQAINRM IQLTLEVSRG VAHWGQQQIR PIKSVIPSPT TTDVTHQNTG KLLKKEERSF EEAIPARKLK NFYPGVAEHK DISKLVLLLS SSVNSLRKAA HEALQDFQKY KTLWTEDRDV KVKEFLANNP SLTEIRSEIL HYATFEQEID ELKPIIVVGA LELHTEPMKL ALSIEAKAWK MLLCRYLNEE YKKKMSYMIA FINEYLKKLS RPIRDLDDVR FAMEALSCIR DNEIQMDMTL GPIEEAYAIL NRFEVEVTKE ESEAVDTLRY SFNKLQSKAV SVQEDLVQVQ PKFKSNLLES VEVFREDVIN FAEAYELEGP MVPNIPPQEA SNRLQIFQAS FDDLWRKFVT YSSGEQLFGL PVTDYEVLHK TRKELNLLQK LYGLYDTVMS SISGYYEILW GDVDIEKINA ELLEFQNRCR KLPKGLKDWQ AFLDLKKRID DFSESCPLLE MMTNKAMKQR HWDRISELTG TPFDVESDSF CLRNIMEAPL LKHKDDIEDI CISAIKEKDI EAKLTQVIEN WTNQNLSFAA FKGKGELLLK GTESGEIITL MEDSLMVLGS LLSNRYNAPF KKNIQNWVYK LSTSSDIIEE WLVVQNLWVY LEAVFVGGDI AKQLPQEAKR FQNIDKSWIK IMQRAHENPN VINCCVGDET MGQLLPHLHE QLEVCQKSLT GYLEKKRLLF PRFFFVSDPV LLEILGQASD SHTIQPHLPA VSDNINEVTF HAKDYDRIMA VISREGEKIV LDNSVMAKGP VEIWLLDLLK MQMSSLHNII RSAFYQISDS GFQLLPFLSH FPAQVGLLGI QMLWTHDSEE ALRNAKDDRK IMQVTNQKFL DILNTLISQT THDLSKFDRV KFETLITIHV HQRDIFDDLV KMHIKSPTDF EWLKQSRFYF KEDLDQTVVS ITDVDFIYQN EFLGCTDRLV ITPLTDRCYI TLAQALGMNM GGAPAGPAGT GKTETTKDMG RCLGKYVVVF NCSDQMDFRG LGRIFKGLAQ SGSWGCFDEF NRIELPVLSV AAQQIYIVLT ARKERKKQFI FSDGDCVDLN PEFGIFLTMN PGYAGRQELP ENLKIQFRTV AMMVPDRQII MRVKLASCGF LENVILAQKF YVLYKLCEEQ LTKQVHYDFG LRNILSVLRT LGSQKRARPE DSELSIVMRG LRDMNLSKLV DEDEPLFLSL INDLFPGLQL DSNTYAELQN AVAHQVQIEG LINHPPWNLK LVQLYETSLV RHGLMTLGPS GSGKTTVITI LMKAQTECGR PHREMRMNPK AITAPQMFGR LDTATNDWTD GIFSTLWRKT LKAKKGENIF LILDGPVDAI WIENLNSVLD DNKTLTLANG DRIPMAPSCK LLFEVHNIEN ASPATVSRMG MVYISSSALS WRPILQAWLK KRTAQEAAVF LTLYEKVFED TYTYMKLNLN PKMQLLECNY IVQSLNLLEG LIPSKEEGGV SCVEHLHKLF VFGLMWSLGA LLELESREKL EAFLRQHESK LDLPEIPKGS NQTMYEFYVT DYGDWEHWNK KLQPYYYPTD SIPEYSSILV PNVDNIRTNF LIDTIAKQHK AVLLTGEQGT AKTVMVKAYL KKYDPEVQLS KSLNFSSATE PMMFQRTIES YVDKRIGSTY GPPGGRKMTV FIDDINMPVI NEWGDQITNE IVRQMMEMEG MYSLDKPGDF TTIVDVQLIA AMIHPGGGRN DIPQRLKRQF TVFNCTLPSN ASIDKIFGII GCGYFDPCRS FKPQICEMIV NLVSVGRVLW QWTKVKMLPT PSKFHYIFNL RDLSRIWQGM LTIKAEECAS IPTLLSLFKH ECSRVIADRF ITPEDEQWFN AHLTRAVEEN IGSDAASCIL PEPYFVDFLR EMPEPTGDEP EDSVFEVPKI YELMPSFDFL AEKLQFYQRQ FNEIIRGTSL DLVFFKDAMT HLIKISRIIR TSCGNALLVG VGGSGKQSLS RLASFIAGYQ IFQITLTRSY NVTNLTDDLK ALYKVAGADG KGITFIFTDS EIKDEAFLEY LNNLLSSGEI SNLFARDEMD EITQGLISVM KRELPRHPPT FDNLYEYFIS RSRKNLHVVL CFSPVGEKFR ARSLKFPGLI SGCTMDWFSR WPREALIAVA SYFLSDYNIV CSSEIKRQVV ETMGLFHDMV SESCESYFQR YRRRAHVTPK SYLSFINGYK NIYAEKVKFI NEQAERMNIG LDKLMEASES VAKLSQDLAV KEKELAVASI KADEVLAEVT VSAQASAKIK NEVQEVKDKA QKIVDEIDSE KVKAESKLEA AKPALEEAEA ALNTIKPNDI ATVRKLAKPP HLIMRIMDCV LLLFQKKIDP VTMDPEKSCC KPSWGESLKL MSATGFLWSL QQFPKDTINE ETVELLQPYF NMDDYTFESA KKVCGNVAGL LSWTLAMAIF YGINREVLPL KANLAKQEGR LAVANAELGK AQALLDEKQA ELDKVQAKFD AAMNEKMDLL NDADTCRKKM QAASTLIDGL SGEKIRWTQQ SKEFKAQINR LVGDILLCTG FLSYLGPFNQ IFRNYLLKDQ WEMELRARKI PFTENLNLIS MLVDPPTIGE WGLQGLPGDD LSIQNGIIVT KATRYPLLID PQTQGKTWIK SKEKENDLQV TSLNHKYFRT HLEDSLSLGR PLLIEDIHEE LDPALDNVLE KNFIKSGTTF KVKVGDKECD IMDTFKLYIT TKLPNPAFTP EINAKTSVID FTVTMKGLEN QLLRRVILTE KQELEAERVK LLEDVTFNKR KMKELEDNLL YKLSATKGSL VDDESLIGVL RTTKQTAAEV SEKLHVAAET EIKINAAQEE FRPAATRGSI LYFLITEMSM VNIMYQTSLA QFLKLFDQSM ARSEKSPLPQ KRITNIIEYL TYEVFTYSVR GLYENHKFLF VLLMTLKIDL QRGTVKHREF QALIKGGAAL DLKACPPKPY RWILDMTWLN LVELSKLPQF AEIMNQISRN EKGWKSWFDK DAPEEEIIPD GYNDSLDTCH KLLLIRSWCP DRTVFQARKY IADSLEEKYT EPVILNLEKT WEESDTRTPL ICFLSMGSDP TNQIDALAKK LKLECRTISM GQGQEVHARK LIQMSMQQGG WVLLQNCHLG LEFMEELLET LITTEASDDS FRVWITTEPH DRFPITLLQT SLKFTNEPPQ GVRAGLKRTF AGINQDLLDI SNLPMWKPML YTVAFLHSTV QERRKFGPLG WNIPYEFNSA DFSASVQFIQ NHLDECDIKK GVSWNTVRYM IGEVQYGGRV TDDFDKRLLN CFARVWFSEK MFEPSFCFYT GYKIPLCKTL DQYFEYIQSL PSLDNPEVFG LHPNADITYQ SNTASAVLET ITNIQPKESG GGVGETREAI VYRLSEDMLS KLPPDYIPHE VKSRLIKMGH LNSMNIFLRQ EIDRMQRVIS ILRSSLSDLK LAIEGTIIMS ENLRDALDNM YDARIPQLWK RVSWDSSTLG FWFTELLERN AQFSTWIFEG RPNVFWMTGF FNPQGFLTAM RQEVTRAHKG WALDTVTIHN EVLRQTKEEI TSPPGEGVYI YGLYMDGAAW DRRNGKLMES TPKVLFTQLP VLHIFAINST APKDPKLYVC PIYKKPRRTD LTFITVVYLR TVLSPDHWIL RGVALLCDIK
Explore Dynein axonemal heavy chain 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets